Top View
- Carbidopa-Levodopa-Entacapone (Stalevo)
- Launch of Ongentys® Tablets 25Mg, a Peripheral COMT Inhibitor in Japan
- Parkinson's Treatment “Tips & Pearls”
- Parkinson's Disease
- High-Risk Medications in the Elderly
- PSP: Some Answers
- Ongentys) Reference Number: CP.PMN.245 Effective Date: 09.01.20 Last Review Date: 08.20 Line of Business: Commercial, HIM, Medicaid Revision Log
- TASMAR* (Tolcapone) RATIONALE for INCLUSION in PA PROGRAM
- Attachment: Product Information for Opicapone
- Safinamide (Xadago) Reference Number: ERX.NPA.45 Effective Date: 09.01.17 Last Review Date: 02.21 Line of Business: Commercial, Medicaid Revision Log
- Highlighted the Attributes of Dupixent. Syed Mahmod from PYC Therapeutic: Highlighted the Attributes of Emflaza
- Mammalian Dopa Decarboxylase: Structure, Catalytic Activity and Inhibition Q ⇑ Mariarita Bertoldi
- TASMAR® (Tolcapone) TABLETS
- Parkinson's Disease Medications
- Medications Approved for the Treatment of Parkinson's Disease In
- Levodopa/Carbidopa/Entacapone Orion, INN-Levodopa, Carbidopa
- Practical Guidelines for Management of Parkinson Disease
- Tasmar (Tolcapone) Is a Selective and Reversible Inhibitor of Catechol-O-Methyltransferase (COMT)
- XADAGO (Safinamide) Tablets, for Oral Use • May Cause Or Exacerbate Dyskinesia; Consider Levodopa Dose Reduction Initial U.S
- Methylene Blue Causing Serotonin Syndrome Following Cystocele Repair
- Gout Induced by L-Dopa and Decarboxylase Inhibitors
- Managing the Neuropsychiatric Symptoms of Dementia in Older Adults Jessica Pyhtila, Pharmd, BCPS, BCGP
- Fine Structure and Biochemical Mechanisms Underlying Nigrostriatal Inclusions and Cell Death After Proteasome Inhibition
- Parkinson's Disease: Carbidopa, Nausea, and Dyskinesia
- Overview of Parkinson's Disease Treatment Options
- ONGENTYS® (Opicapone) Capsules Patient Brochure
- LEVODOPA 2.0: NEW STRATEGIES to EVEN out the PEAKS and VALLEYS Written by Rachel Dolhun, MD Medical Communications, the Michael J
- Spectroscopic Analysis of Recombinant Rat Histidine Decarboxylasel
- Purification of Lysine Decarboxylase: a Model System for Plp Enzyme Inhibitor Development and Study
- Medication Glossary- Drug Classes and Medication
- Entacapone-Containing Products – Safety Update
- A Treatment Guide to Parkinson's Disease
- Tasmar, INN-Tolcapone
- The Aromatic-L-Amino Acid Decarboxylase Inhibitor Carbidopa Is Selectively Cytotoxic to Human Pulmonary Carcinoid and Small Cell Lung Carcinoma Cells1
- New Zealand Data Sheet Tasmar®
- (12) Patent Application Publication (10) Pub. No.: US 2004/0101523 A1 Reitz Et Al
- Stalevo 100 (Carbidopa, Entacapone and Levodopa)
- Aromatic Amino Acid Decarboxylase Deficiency
- 2017 New Drug Therapy Approvals Report
- Dietary Influence of Tyrosine and Phenylalanine on the Response of B16 Melanoma to Carbidopa-Levodopa Methyl Ester Chemotherapy1
- Neurocrine Biosciences Announces FDA Approval of Once-Daily
- Lodosyn (Carbidopa) Tablets
- Medical Management of Parkinson's Disease
- Medical Necessity Criteria for Pharmacy Edits, 5.01.605
- Inbrija (Levodopa) Nourianz (Istradefylline) Effective 09/01/2020
- A Peripheral COMT Inhibitor for the Improvement of Parkinson’S Disease Patients with Motor Fluctuations
- Levodopa, Carbidopa, Entacapone > Printer-Friendly PDF
- PD Medications: Managing Side Effects Led By
- Sinemet (Carbidopa-Levodopa) Tablets
- Carbidopa, Entacapone and Levodopa
- CARBIDOPA and LEVODOPA- Carbidopa and Levodopa Tablet, Extended Release ETHEX
- Ongentys) Reference Number: ERX.NPA.144 Effective Date: 09.01.20 Last Review Date: 08.20 Line of Business: Commercial, Medicaid Revision Log
- Safinamide (Xadago) Reference Number: PA.CP.PMN.113 Effective Date: 04.17.19 Last Review Date: 04.19 Revision Log
- Developing Selective L-Amino Acid Transport 1 (LAT1) Inhibitors: a Structure-Activity Relationship Overview Authors
- Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: a Critical Review on Clinical and Pharmacological Management
- Dopamine Agonist Initiating Therapy in Early PD Patients: When Do We Initiate Therapy?
- Design, Synthesis and Characterization of Coenzyme-Substrate Inhibitors Targeting Intracellular Pyridoxal 5’-Phosphate
- Prior Authorization — Premium
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- WHO Model List of Essential Medicines
- Which Drugs Work Best for Early Parkinson's Disease?
- Ongentys (Opicapone) – New Drug Approval
- Xadago® (Safinamide)
- Xadago (Safinamide), Indicated As Adjunctive Treatment to Levodopa/Carbidopa in Patients with Parkinson’S Disease (PD) Experiencing “Off” Episodes
- Sinemet CR PI
- Prescribing Information
- Information for the User Levodopa/Carbidopa Retard STADA
- Increased Dose of Carbidopa with Levodopa and Entacapone Improves “Off” Time in a Randomized Trial
- COMT Inhibitors
- Maximizing PD Medications: How to Get the Most out of Your Treatment Plan
- Package Leaflet: Information for the Patient Levodopa/Carbidopa
- CP.PMN.113 Safinamide (Xadago)
- Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from Turnera Diffusa (Damiana)
- Serotonin Syndrome in Parkinson Disease Ni{/L[(' M
- Role of Kynurenine Pathway in Oxidative Stress During Neurodegenerative Disorders
- ONGENTYS (Opicapone) Capsules, for Oral Use • Dyskinesia: May Cause Or Exacerbate Dyskinesia; Consider Levodopa Or Initial U.S
- Medications in Patients with Advanced PD Side Effects